DCGI: Current Affairs, GK & News - 2020-2021

Indian Company Zydus Cadila Starts Clinical Trial for COVID 19 Vaccine

Published: July 16, 2020

The Indian pharmaceutical behemoth, Zydus Cadila, has started the Phase I, II clinical trials for its COVID 19 vaccine. The pharma giant had received approval from the Drug Controller General of India for clinical trials earlier this month. The company has started its trial with 1048 subjects by intradermal injection route. The Clinical Trial Registry ..

Month: 

Category: 

Topics: 

First indigenously developed Pneumococcal Polysaccharide Conjugate Vaccine Approved by DCGI

Published: July 15, 2020

The first-ever completely home-grown Pneumococcal Polysaccharide Conjugate Vaccine has been approved by the Drug Controller General of India. The vaccine has been developed by Serum Institute of India, Pune. Serum Institute of India is also involved in the development of COVID 19 vaccine. The DCGI had given approval earlier to Serum Institute of India to ..

Month: 

Category: 

Topics: 

DCGI allows use of “Itolizumab” for moderate to severe COVID-19 cases

Published: July 11, 2020

On July 11, 2020, the Dugs Controller General of India (DCGI) granted restricted emergency use of Itolizumab for moderate to severe COVI-19 patients. Highlights Itolizumab is a monoclonal antibody that was already approved for chronic plaque psoriasis. The drug will now be used to treat COVID-19 based on clinical trials. The drug was manufactured and ..

Month: 

Category: 

Topics: 

CSIR: Clinical Trial of “Sepsivac” drug on critically ill COVID-19 patients

Published: April 22, 2020

On April 22, 2020, the Council of Scientific and Industrial Research announced that it is to go for clinical trials on critically ill COVID-19 patients. Background The Drugs Controller General of India recently approved the trial of “Sepsivac”. The drug is available commercially. With the DCGI approving the drug, CSIR is to start clinical trials ..

Month: 

Category: 

Topics: 

DCGI approves COVID-19 drug to reduce mortality rate

Published: April 21, 2020

On April 20, 2020, the Drugs Controller General of India (DCGI) approved trial of a drug to reduce mortality rate of COVID-19 patients. Highlights The COVID-19 drug that was developed by the Cadila Pharmaceuticals along with Council of Scientific and Industrial Research (CSIR) is to enter into trial. The clinical trial has been approved by ..

Month: 

Category: 

Topics: 

Advertisement